Agile Therapeutics, Inc.

AGRX

US00847L3087

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 02:49:55 2023-12-01 pm EST			5-day change	1st Jan Change
2.148 ^USD	+1.80%		+0.85%	-81.07%

Nov. 09	Agile Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
Nov. 09	Transcript : Agile Therapeutics, Inc., Q3 2023 Earnings Call, Nov 09, 2023	CI

Agile Therapeutics, Inc. announced that it has received $45 million in funding from Perceptive Advisors LLC

March 28, 2021

On March 1, 2021, the company amended the terms of the transaction. The company now raised $45 million in the transaction. The investor provided additional $10 million in its fourth tranche close.

Latest news about Agile Therapeutics, Inc.

Agile Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Transcript : Agile Therapeutics, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09	CI
Agile Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023	Nov. 09	CI
Earnings Flash (AGRX) AGILE THERAPEUTICS Reports Q3 Revenue $6.7M, vs. Street Est of $6.35M	Nov. 09	MT
North American Morning Briefing : Traders Await -2-	Nov. 09	DJ
North American Morning Briefing : Stock Futures -2-	Sep. 25	DJ
Maxim Upgrades Agile Therapeutics to Buy From Hold With $5 Price Target	Sep. 22	MT
Agile Therapeutics, Inc. Affirms Revenue Guidance for the Year 2023	Aug. 09	CI
Transcript : Agile Therapeutics, Inc., Q2 2023 Earnings Call, Aug 09, 2023	Aug. 09	CI
Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q2 Revenue $5.5M	Aug. 09	MT
Agile Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	Aug. 09	CI
Agile Therapeutics, Inc. Provides Revenue Guidance for the Year 2023	Jun. 30	CI
Agile Therapeutics, Inc. Announces Executive Changes	Jun. 27	CI
Agile Therapeutics, Inc. Appoints Scott Coiante as Chief Financial Officer	Jun. 27	CI
Agile Therapeutics Announces the Availability of Twirla® through FPA Women’s Health	Jun. 15	CI
Agile Therapeutics, Inc. Announces New Agreement with vitaCare Prescription Services to Improve Access to Twirla	Jun. 13	CI
Agile Therapeutics, Inc. announced an agreement to acquire vitaCare Prescription Services, Inc. from GoodRx Holdings, Inc..	Jun. 12	CI
Agile Therapeutics Closes $7.5 Million Public Offering	May. 26	MT
Agile Therapeutics Prices $7.5 Million Public Offering of Common Stock, Warrants	May. 23	MT
Transcript : Agile Therapeutics, Inc., Q1 2023 Earnings Call, May 11, 2023	May. 11	CI
Agile Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	May. 11	CI
Agile Therapeutics, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2023	May. 11	CI
Earnings Flash (AGRX) AGILE THERAPEUTICS Reports Q1 Revenue $3.8M	May. 11	MT
Agile Therapeutics, Inc. Provides Revenue Guidance for the First Quarter 2023	Apr. 28	CI
Agile Therapeutics Gets Board Approval for 1-For-50 Reverse Stock Split	Apr. 10	MT

Chart Agile Therapeutics, Inc.

Duration

Period

More charts

Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. The Company's sole approved product, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch. Twirla is a method of contraception for use in women of reproductive potential for whom a combined hormonal contraceptive is appropriate. Twirla is a prescription combined hormonal contraceptive patch, which contains the active ingredients ethinyl estradiol (EE), which is a synthetic estrogen and levonorgestrel (LNG), which is a type of progestin. Twirla delivers 30 micrograms of EE per day, a dose of EE consistent with the dose delivered by many commonly prescribed oral contraceptives. The Company commercializes Twirla in the United States. Twirla leverages the Company's transdermal patch technology called Skinfusion. Skinfusion is designed to allow drug delivery through the skin while optimizing patch adhesion and patient comfort and wearability.

Sector

Biotechnology & Medical Research

Calendar

2024-03-11 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Agile Therapeutics, Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.110USD

Average target price

8.500USD

Spread / Average Target

+302.84%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AGILE THERAPEUTICS, INC.	-81.07%	5 M $
VERTEX PHARMACEUTICALS INCORPORATED	+21.48%	91 429 M $
REGENERON PHARMACEUTICALS, INC.	+12.46%	87 610 M $
WUXI APPTEC CO., LTD.	+2.47%	34 419 M $
ARGENX SE	+19.81%	26 250 M $
BIONTECH SE	-34.67%	23 869 M $
GENMAB A/S	-26.62%	20 655 M $
BEIGENE, LTD.	-15.18%	19 460 M $
NEUROCRINE BIOSCIENCES, INC.	-2.36%	11 455 M $
LEGEND BIOTECH CORPORATION	+20.17%	11 056 M $